110 related articles for article (PubMed ID: 7728769)
1. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
Shi Y; Frankel A; Radvanyi LG; Penn LZ; Miller RG; Mills GB
Cancer Res; 1995 May; 55(9):1982-8. PubMed ID: 7728769
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells.
Bae-Jump VL; Zhou C; Boggess JF; Gehrig PA
Cancer; 2009 Sep; 115(17):3887-96. PubMed ID: 19484784
[TBL] [Abstract][Full Text] [Related]
3. Murine TRAIL (TNF-related apoptosis inducing ligand) expression induced by T cell activation is blocked by rapamycin, cyclosporin A, and inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and protein tyrosine kinases: evidence for TRAIL induction via the T cell receptor signaling pathway.
Musgrave BL; Phu T; Butler JJ; Makrigiannis AP; Hoskin DW
Exp Cell Res; 1999 Oct; 252(1):96-103. PubMed ID: 10502402
[TBL] [Abstract][Full Text] [Related]
4. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
Kuo CJ; Chung J; Fiorentino DF; Flanagan WM; Blenis J; Crabtree GR
Nature; 1992 Jul; 358(6381):70-3. PubMed ID: 1614535
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase (PI-3K)/Akt but not PI-3K/p70 S6 kinase signaling mediates IGF-1-promoted lens epithelial cell survival.
Chandrasekher G; Sailaja D
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3577-88. PubMed ID: 15452065
[TBL] [Abstract][Full Text] [Related]
7. Curcumin enhances Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells.
Wahl H; Tan L; Griffith K; Choi M; Liu JR
Gynecol Oncol; 2007 Apr; 105(1):104-12. PubMed ID: 17174384
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
10. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
12. Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis.
Radvanyi LG; Shi Y; Mills GB; Miller RG
Cell Immunol; 1996 Jun; 170(2):260-73. PubMed ID: 8660826
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Aissat N; Le Tourneau C; Ghoul A; Serova M; Bieche I; Lokiec F; Raymond E; Faivre S
Cancer Chemother Pharmacol; 2008 Jul; 62(2):305-13. PubMed ID: 17912526
[TBL] [Abstract][Full Text] [Related]
14. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment.
Azuma H; Takahara S; Horie S; Muto S; Otsuki Y; Katsuoka Y
J Urol; 2003 Jun; 169(6):2372-7. PubMed ID: 12771800
[TBL] [Abstract][Full Text] [Related]
15. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.
Ma PC; Schaefer E; Christensen JG; Salgia R
Clin Cancer Res; 2005 Mar; 11(6):2312-9. PubMed ID: 15788682
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
17. Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitro.
Zhang JF; Liu JJ; Lu MQ; Cai CJ; Yang Y; Li H; Xu C; Chen GH
Transpl Immunol; 2007 Apr; 17(3):162-8. PubMed ID: 17331842
[TBL] [Abstract][Full Text] [Related]
18. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
[TBL] [Abstract][Full Text] [Related]
19. c-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-kappa B activity in pancreatic cancer cells.
Biliran H; Banerjee S; Thakur A; Sarkar FH; Bollig A; Ahmed F; Wu J; Sun Y; Liao JD
Clin Cancer Res; 2007 May; 13(9):2811-21. PubMed ID: 17473215
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]